Biotie Therapies - Company Announcement

Nalmefene United Kingdom and Ireland rights acquired by Lundbeck

BIOTIE THERAPIES CORP.         STOCK EXCHANGE RELEASE
                               January 2, 2008


NALMEFENE UNITED KINGDOM AND IRELAND RIGHTS ACQUIRED BY LUNDBECK


Lundbeck has acquired the United Kingdom and Ireland rights for
nalmefene from Britannia Pharmaceuticals (now part of STADA Group,
headquartered in Germany). Following the new agreement Lundbeck has
worldwide rights for nalmefene, excluding North America, Mexico,
Turkey, and South-Korea.

Biotie-Lundbeck license agreement terms have been amended due to
Lundbeck acquiring the United Kingdom and Ireland rights. Under the
terms of the amended agreement, Biotie is now eligible for up to EUR
82 million in upfront and milestone payments (previously up to EUR 80
million) plus royalty on sales. Of the EUR 82 million, Biotie has
already received an execution fee of EUR 12 million from Lundbeck.

The intention is to seek marketing authorisation for nalmefene in the
treatment of alcoholism simultaneously in all 27 EU member states via
the centralized procedure. To this end, Lundbeck plans to further
strengthen the existing nalmefene registration dossier in its
alcoholism indication with additional phase III clinical studies
before submitting the marketing authorisation application. The
studies are expected to start in 2008.

Timo Veromaa, President and CEO of Biotie, said: "Lundbeck now owning
all of nalmefene rights in the EU is very positive development indeed
for Biotie. This significantly facilitates EU-wide regulatory and
marketing activities. We remain confident that nalmefene will
generate significant revenues to the company in the long term."



Turku, 2 January, 2008


Biotie Therapies Corp.


Timo Veromaa
President and CEO

For further information, please contact:

Timo Veromaa, President and CEO, Biotie Therapies Corp.
tel. +358 2 274 8901, e-mail: timo.veromaa@biotie.com
www.biotie.com

Distribution: OMX Nordic Exchange Helsinki
              Main Media




Biotie Therapies Corp.

Biotie is a Finnish biotech company with focus on dependence
disorders, inflammatory diseases and thrombosis.
www.biotie.com





About nalmefene
Nalmefene is a specific opioid receptor antagonist. Biotie has
studied the safety and efficacy of nalmefene in a total of 1,200
patients, including two phase III studies in the UK and Finland in
patients suffering from alcoholism and alcohol dependence.

Nalmefene is the first oral drug showing efficacy in reducing heavy
drinking in multicenter, controlled studies.

The treatment of alcoholism represents a significant unmet medical
need. More than 30 million people in the US, Europe and Japan suffer
from alcohol abuse (Datamonitor 04/2002). Every year, in the UK
alone, there are 150,000 hospital admissions and 20,000 premature
deaths directly due to alcohol, 1.2 million alcohol related violent
incidents, and National Health Service estimates the annual costs of
alcohol abuse to range between GBP 1.4 billion and GBP 1.7 billion.